AKOME BIOTECH
Akome Biotech is a developer of psychedelic-based pharmaceuticals for rare diseases and mental disorders targeting treatments for Cluster Headaches (CH), Alzheimer's Disease (AD), and Depression.
AKOME BIOTECH
Industry:
Biotechnology Neuroscience Pharmaceutical
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.akomebiotech.com
Status:
Active
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Amazon SSL By Default Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS AWS Global Accelerator
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Palo Santo Fund
Palo Santo Fund is an investment fund that invests in psychedelic and healthcare industry.
Current Employees Featured
Official Site Inspections
http://www.akomebiotech.com
- Host name: 20.105.215.35.bc.googleusercontent.com
- IP address: 35.215.105.20
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Akome Biotech"
Akome Biotech - Crunchbase Company Profile & Funding
Akome Biotech is a developer of psychedelic-based pharmaceuticals for rare diseases and mental disorders targeting treatments for Cluster Headaches …See details»
About Us – Akome Biotech
Akome is a researcher and developer of psychedelic-based pharmaceuticals for the purpose of addressing of neurological and mental health disorders with an initial focus on targeting …See details»
Leadership – Akome Biotech
Akome’s CEO, Dr. Santiago Ferro has extensive experience leading clinical research teams and has been involved in all aspects of start-up companies and product life cycles: from product …See details»
Akome Biotech Company Profile 2024: Valuation, …
Akome Biotech General Information Description. Developer of psychedelic-based pharmaceuticals specializing aimed at treating rare diseases and mental disorders. The company makes drugs for the treatment of cluster headaches, …See details»
Akome Biotech - Products, Competitors, Financials, Employees ...
Akome Biotech is developing psychedelic-based pharmaceuticals to help patients with stroke, and neurological and mental conditions. On April 23, 2021, Akome Biotech was acquired by Core …See details»
Akome Biotech Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Www.akomebiotech.com. Last update 23 Jan 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. ... The …See details»
Core One Labs (COOL.C) Completes Acquisition of Akome Biotech
May 4, 2021 Moreover, approximately 6.8 million people die from neurological diseases each year according to a report published by the World Health Organization (WHO). With this in …See details»
Akome Biotech - Overview, News & Similar companies - ZoomInfo
Aug 7, 2021 Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development VANCOUVER, British Columbia, Aug. 07, 2021 …See details»
Akome Biotech | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Core One Labs Reaches Definitive Agreement to Acquire Akome …
Apr 29, 2021 Core One Labs Inc. 3123 – 595 Burrard Street, Vancouver, BC V7X 1J1 +1 (888) 45CORE1 (452-6731) [email protected]See details»
Core One Labs Completes Milestone Acquisition of Akome Biotech
May 4, 2021 Vancouver, British Columbia, Canada – May 4, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a …See details»
Akome Biotech Ltd. (Akome Biotech Ltd.) - 药物管线_专利_临床试 …
了解Akome Biotech Ltd. (Akome Biotech Ltd.)公司的药物管线，治疗领域，技术平台，以及它的3篇新闻，疾病领域:神经系统疾病，内分泌与代谢疾病，技术平台:小分子化药，药物:AKO …See details»
Core One Labs’ Akome Achieves Another Milestone in …
Aug 19, 2022 Vancouver, British Columbia, Canada – August 19, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core …See details»
Core One Labs completes acquisition of Akome Biotech
Akome’s proprietary cGMP drug formulations comprising psychedelic compounds and plant bioactives distinguish its approach on the psychedelic treatment of neurological disorders from …See details»
Core One Labs': Akome Achieves Significant Research Milestone …
Aug 23, 2022 Core One Labs Inc. (CSE: COOL | OTCQB:CLABF | Frankfurt:LD6 | WKN:A3CSSU), further to its press release dated March 4, 2022, is excited to announce its …See details»
Core One Labs Completes Milestone Acquisition of Akome Biotech
May 4, 2021 VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or …See details»
Core One Labs’ Akome Biotech Initiates Neurogenesis
Mar 4, 2022 VANCOUVER, British Columbia, March 04, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the...See details»
CORE ONE LABS’ AKOME BIOTECH PROTECTS NEW AK0003 …
Jul 21, 2021 Vancouver, British Columbia, Canada – July 21, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to …See details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different …See details»
Core One’s Akome Reveals Groundbreaking Positive Results from …
Aug 4, 2023 Vancouver, British Columbia, Canada – August 4, 2023 – Core One Labs Inc. (CSE: COOL) (OTCQB: CLABF) (Frankfurt: LD6, WKN: A3CSSU), (the “Company” or “Core …See details»